UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug

ViiV Healthcare, a GSK unit, has received a positive recommendation from the UK's National Institute for Health and Care Excellence (NICE) for its HIV preventive drug, Apretude, enabling its funding and access through the NHS in England and Wales. This decision expands market penetration for the injectable drug, which generated £279 million ($374.95 million) in global sales last year, intensifying competition with Gilead's established oral and long-acting treatments in the pre-exposure prophylaxis (PrEP) market.

Analysis

ViiV Healthcare, a GSK unit, has secured a positive recommendation from the UK's National Institute for Health and Care Excellence (NICE) for its HIV preventive drug, Apretude. This regulatory milestone enables routine funding and access through the National Health Service (NHS) in England and Wales, with availability expected within two to three months. This significantly expands Apretude's market penetration in a key European region.

Apretude, an injectable pre-exposure prophylaxis (PrEP), offers a crucial alternative for individuals who prefer not to use or cannot tolerate oral HIV prevention medications. The drug, which already holds US approval since late 2021 and European approval since 2023, generated £279 million ($374.95 million) in global sales last year, indicating its established commercial viability.

The NICE approval intensifies competition within the PrEP market, where Apretude directly challenges Gilead's established oral treatments, Truvada and Descovy, and its long-acting injectable, Yeztugo. While Apretude requires dosing every two months compared to Yeztugo's six-month regimen, GSK is actively exploring a longer-acting version that could potentially extend dosing intervals to four months or more, aiming to enhance its competitive profile.

Key Decisions for Investors

• Investors in GSK should recognize the positive NICE recommendation for Apretude as a significant catalyst for market share expansion and revenue growth within its pharmaceutical segment, particularly in the UK.
• Monitor Apretude's sales trajectory and the progress of GSK's longer-acting formulation development, as these factors will be critical indicators of its sustained competitive advantage against rivals like Gilead.
• Gilead investors should evaluate the potential impact of Apretude's increased market penetration on its established PrEP portfolio, as intensified competition could pressure market share and future sales in this therapeutic area.